Skip to main content

ORIGINAL RESEARCH article

Front. Physiol.
Sec. Renal Physiology and Pathophysiology
Volume 15 - 2024 | doi: 10.3389/fphys.2024.1440799

Graft-derived cell free DNA:Used for assessment of early graft status and its implications for long-term kidney function

Provisionally accepted
Liang Wei Liang Wei 1Yongheng Zhao Yongheng Zhao 1Shaoping Deng Shaoping Deng 1Shaoping Wu Shaoping Wu 2Hailian Wang Hailian Wang 3,4Xiangwei Luo Xiangwei Luo 3,4Hongji Yang Hongji Yang 3,4*
  • 1 Transplantation Health Management Center, Sichuan Taikang Hospital, Chengdu, Sichuan, Chengdu, Sichuan, China
  • 2 Department of Radiology, Sichuan Taikang Hospital, Chengdu, Sichuan, Chengdu, Sichuan, China
  • 3 Clinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, Sichuan Province, China
  • 4 Transplantation Center, Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Chengdu, Sichuan Province, China

The final, formatted version of the article will be published soon.

    The long-term graft survival is closely related to its early status, yet the indices for assessing the early graft status are complex and lack quantitative values. The aim of this study is to investigate the potential of GcfDNA as a comprehensive, non-invasive, convenient, and quantifiable indicator for evaluating early graft status.Methods: In this study, 138 recipients who underwent primary kidney transplantation were enrolled.Peripheral blood samples, each 10 mL, were collected on days 1 and 7 post-transplantation. The quantification of both the graft cell-free DNA (GcfDNA) fraction (%) and GcfDNA concentration (copies per milliliter, cp/mL) was performed using droplet digital PCR (ddPCR).Results: For most recipients, both the GcfDNA fraction and concentration had a rapid decline at 7 days post-transplantation, reaching median values of approximately 0.7% and 53.5 cp/mL, respectively. No significant associations were found between GcfDNA values and other clinical parameters. On the 7th postoperative day, we observed a significant elevation in GcfDNA concentration among recipients with eGFR values <60 mL/min/1.73m². Additionally, notable increases were identified in both GcfDNA fraction and concentration variations within this specific subgroup. The findings of our study indicate a negative correlation between the concentration and fractional changes of GcfDNA on postoperative days 1 and 7, as well as the GcfDNA concentration on postoperative day 7, with eGFR within the 1 to 2 years post-transplantation period. The ROC curve of GcfDNA_Copies_Variation. day1-day7 showed the highest AUC value AUC=0.8006, with high sensitivity (90.14%) and specificity (77.61%), and PPV and NPV were 81.01% and 88.14%, respectively. Using four classical algorithm models, we found that the xgboost regression model achieved the best predictive performance (area under the curve (AUC) values=0.862) for eGFR within 1 to 2 years post-transplantation, with high sensitivity (85.7%) and specificity (85%).The changes of GcfDNA levels in the early stage are closely related to kidney function within 1-2 years post-transplantation. As a comprehensive indicator of graft function, GcfDNA has great potential for clinical application.

    Keywords: Graft-derived cell-free DNA, Kidney Transplantation, Estimated glomerular filtration rate, EGFR, kidney graft function

    Received: 30 May 2024; Accepted: 04 Nov 2024.

    Copyright: © 2024 Wei, Zhao, Deng, Wu, Wang, Luo and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Hongji Yang, Clinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, Sichuan Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.